Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 2/20 | 0.31 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.30 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.30 |
| ▸ | HTR3B | O95264 | 1/20 | 0.30 |
| ▸ | HTR3A | P46098 | 1/20 | 0.30 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.30 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29955036 | 0.73 | CYP1A2 (0.39) | AR | |
| SCHEMBL7124314 | 0.73 | NOTUM (0.52) | NOTUMHTR3A | |
| SCHEMBL8350547 | 0.71 | TNF (0.33) | — | |
| SCHEMBL8436824 | 0.70 | CYP3A4 (0.40) | — | |
| SCHEMBL2991016 | 0.70 | NOTUM (0.41) | P2RX7CLCN2NOTUMHTR3EHTR3B | |
| SCHEMBL30524329 | 0.70 | NOTUM (0.41) | P2RX7CLCN2NOTUMHTR3EHTR3B | |
| SCHEMBL7120443 | 0.69 | NOTUM (0.42) | NOTUMHTR3A | |
| SCHEMBL9392558 | 0.69 | EPAS1 (0.40) | P2RX7CLCN2AREPAS1NOTUM | |
| SCHEMBL11878190 | 0.68 | CLCN2 (0.40) | P2RX7CLCN2NOTUM | |
| SCHEMBL3663843 | 0.67 | ALDH1A1 (0.39) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030207865-A1 | Substituted 2-arylimino heterocycles and compositions containing them for use as progesterone receptor binding agents | DIXON BRIAN R (US) | 2003-11-06 | — | — | US | disclosed |
| US-6353006-B1 | TREATMENT OF BONE DISORDERS, OSTEOPOROSIS AND HEALING AGENT | BAYER CORPORATION | 2002-03-05 | — | — | US | disclosed |
| EP-1144396-A2 | SUBSTITUTED 2-ARYLIMINO HETEROCYCLES AND COMPOSITIONS CONTAINING THEM, FOR USE AS PROGESTERONE RECEPTOR BINDING AGENTS | Bayer Corporation (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000042031-A2 | SUBSTITUTED 2-ARYLIMINO HETEROCYCLES AND COMPOSITIONS CONTAINING THEM, FOR USE AS PROGESTERONE RECEPTOR BINDING AGENTS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
| US-5981438-A | HERBICIDE, INSECTICIDE AND PESTICIDE | NIHON BAYER AGROCHEM K.K. (JP) | 1999-11-09 | — | — | US | disclosed |
| EP-0855394-A1 | 1-Phenyl-5-anilinotetrazoles derivatives, their preparation and their use as microbiocides, insecticides and/or herbicides | NIHON BAYER AGROCHEM K.K. (JP) | 1998-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207865-A1 | Substituted 2-arylimino heterocycles and compositions containing them for use as progesterone receptor binding agents | PGR, PGRMC2, PGRMC1 | P2RX7 187/4885CLCN2 3975/4885AR 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.